Oligodendroglial tumor chemotherapy using “decreased-dose-intensity” PCV: A Singapore experience

The authors propose “decreased-dose-intensity” PCV (procarbazine, lomustine [CCNU], and vincristine) chemotherapy for Asian patients with oligodendroglial tumors. In this study, all seven patients with oligodendroglioma (OD) and eight with anaplastic oligodendroglioma (AO) had objective responses or stable disease. Median progression-free survival was greater than 29 months (OD) and 36.5 months or greater (AO); 86% of patients with OD and 63% with AO remain progression-free. Twenty-four Common Toxicity Criteria Grade 3/4 adverse events were noted.

[1]  M. J. van den Bent,et al.  Successful treatment of low‐grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine , 2005, Cancer.

[2]  Peter Bross,et al.  The Metabolic and Molecular Basis of Inherited Disease: Protein Folding and Misfolding: the Role of Cellular Protein Quality Control Systems in Inherited Disorders , 2005 .

[3]  Akira Yamaura,et al.  Treatment of low-grade oligodendroglial tumors without radiotherapy , 2004, Neurology.

[4]  A. Brandes,et al.  Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy , 2004, Cancer.

[5]  S. Diabira,et al.  PCV Chemotherapy for Oligodendroglioma: Response Analyzed on T2 Weighted-MRI , 2001, Journal of Neuro-Oncology.

[6]  H. Engelhard,et al.  Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis. , 2003, Surgical neurology.

[7]  M. Ratain,et al.  Anticancer drug discovery and development throughout the world. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Y. Kajita,et al.  Efficacy of adjuvant therapy with procarbazine, MCNU, and vincristine for oligodendroglial tumors. , 2001, Neurologia medico-chirurgica.

[9]  A. Twijnstra,et al.  Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy , 1998, Neurology.

[10]  S. Levine,et al.  Cerebrovascular complications of Fabry's disease , 1996, Annals of neurology.

[11]  T. Cascino,et al.  Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Tsuji.  [Alpha-galactosidase A deficiency--Fabry's disease]. , 1988, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[13]  K. Takakura,et al.  Effects of ACNU and radiotherapy on malignant glioma. , 1986, Journal of neurosurgery.